Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients
THOUSAN... Biopharmaceuticals, Cardiology, Regulatory Amgen, Repatha, evolocumab, myocardial infarction, stroke
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news